Organization
International Breast Cancer Centre (IBCC)
4 abstracts
Abstract
An age-specific pooled analysis of trastuzumab deruxtecan (T‑DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) from DESTINY-Breast01, -02, and -03.Org: University Hospital Leuven, International Breast Cancer Centre (IBCC), Quironsalud Group, Aichi Cancer Center Hospital, Vall d’Hebron University Hospital/VHIO,
Abstract
Open-label, randomized, multicenter, phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib for treating ER+/HER2-, locally advanced or metastatic breast cancer with an ESR1 mutation.Org: Pangaea Oncology, Breast Oncology Institute, Sermonix Pharmaceuticals, Mayo Clinic, Medical Oncology,
Abstract
Oral elacestrant vs standard-of-care in estrogen receptor-positive, HER2-negative (ER+/HER2-) advanced or metastatic breast cancer (mBC) without detectable ESR1 mutation (EMERALD): Subgroup analysis by prior duration of CDK4/6i plus endocrine therapy (ET).Org: UT Health San Antonio, MD Anderson Cancer Center, Institut Curie, Saint Cloud, France, Universitaire Ziekenhuizen (UZ) - Leuven Cancer Institute, University Hospitals Seidman Cancer Center, Jean Perrin Cancer Centre,
Abstract
The evolving value assessment of cancer therapies: Principles from the cancer community.Org: The Boston Consulting Group, Lung cancer Europe, The Susan G. Komen Breast Cancer Foundation, Inc., Cancer Technology Applications, International Breast Cancer Centre (IBCC),